In summary, our work identifies SNX3 as a novel potential therapeutic target through dual β-catenin pathway modulation, develops LC4 as a novel inhibitor, and establishes TDN-LC4 as a precision nanomedicine for PF treatment. Here, SNX3 is linked to pemphigus foliaceus.